ReviewCureus2025
Testosterone Replacement Therapy in Men Aged 50 and Above: A Narrative Review of Evidence-Based Benefits, Safety Considerations, and Clinical Recommendations.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Review
- Testosterone Replacement Therapy in Athletes: Implications for Injury Recovery and Musculoskeletal Performance.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone replacement therapy (TRT) is a cornerstone in the management of late-onset hypogonadism in men aged 50 years and above, a condition characterized by progressive declines in serum testosterone, impaired sexual and physical function, metabolic disturbances, and reduced quality of life. Although historical concerns have centered on cardiovascular safety and prostate health, contemporary high-quality evidence and clinical guidelines increasingly support TRT when appropriately prescribed and monitored. To synthesize and critically appraise the evidence regarding the benefits, safety profile, and clinical recommendations for TRT in men aged ≥50 years, a comprehensive search of PubMed/MEDLINE, Embase, and the Cochrane Library (January 2000-July 2025) was conducted, identifying randomized controlled trials, cohort studies, systematic reviews, and meta-analyses assessing TRT in this population. Eligible studies reported outcomes in sexual, musculoskeletal, metabolic, cardiovascular, cognitive, and quality-of-life domains, as well as safety endpoints. TRT consistently improved sexual desire, erectile function, lean body mass, bone mineral density, insulin sensitivity, and vitality, with most benefits observed in men with baseline testosterone levels <300 ng/dL and target levels maintained at 500-800 ng/dL. Safety data indicate no increased risk of major adverse cardiovascular events or prostate cancer when guidelines are followed, though erythrocytosis remains the most common dose-related adverse effect. Effect sizes varied according to baseline androgen status, formulation, treatment duration, and comorbidities. TRT in men aged ≥50 with confirmed hypogonadism offers significant, multi-system benefits with a favorable safety profile under structured monitoring. Individualized treatment strategies and further large-scale, long-term trials are needed to refine patient selection, optimize outcomes, and address remaining knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.